A Phase I Trial of Interleukin-2 and Pembrolizumab (MK-3475) Combination Therapy for Patients With Advanced Renal Cell Carcinoma
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Aldesleukin (Primary) ; Aldesleukin (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 02 Mar 2018 Planned initiation date changed from 15 Jan 2018 to 15 Apr 2018.
- 13 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 15 Jan 2018.
- 29 Aug 2017 New trial record